| Bioactivity | Piperilate (Pipethanate) is one of the mixtures of hetrazepine derivative PAF antagonists with anticholinergics, can be used for bronchial asthma research. Piperilate also causes hypotension and rescues mice poisoned by the organophosphates[1][2][3]. |
| In Vivo | Piperilate (11.3 mg/kg, 29.42 mg/kg; i.p.; single dose) shows anticholinergic activity, and (30 mg/kg; i.p.; single dose) exerts efficacy in mice poisoned by the organophosphates[1]. Piperilate (1 mg/kg; i.v.) causes hypotension in rabbit which is not blocked by dichloroisoproterenol or Atropine (HY-B1205)[2].Piperilate (3 mg/kg; i.v.) decreases respiration and heart rate of test rabbits, blocks the Adrenaline (HY-122304)-induced constriction of an isolated rabbit auricle preparation[2]. Animal Model: |
| Name | Piperilate |
| CAS | 4546-39-8 |
| Formula | C21H25NO3 |
| Molar Mass | 339.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Faff J, et al. Therapeutic effects of some cholinolytics in organophosphate intoxications. Arch Toxicol. 1976 Oct 28;36(2):139-46. [2]. Tanaka S, et al. [Studies on pharmacological effect of pipethanate. II. Effect of pipethanate on respiration, circulation system and smooth muscle]. Eisei Shikenjo Hokoku. 1971;89:54-8. Japanese. [3]. Heuer, et al. Synergistic combinations of PAF antagonists and anticholinergic agents as drugs for treatment of bronchial asthma: Germany, DE4219659. 1993-12-23. |